ABT-702

ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research[1][2][3].

Product Specifications

CAS Number

[214697-26-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Kinase; Adenosine Receptor

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Inflammation/Immunology

Purity

99.61

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

BrC1=CC=CC(C2=C3C(N)=NC=NC3=NC(C4=CC=C(N5CCOCC5)N=C4)=C2)=C1

Molecular Formula

C22H19BrN6O

Molecular Weight

463.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Jarvis MF, et al. ABT-702 (4-amino-5- (3-bromophenyl) -7- (6-morpholinopyridin-3-yl) pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther. 2000 Dec;295 (3) :1156-64.|[2]Parkinson FE, et al. The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study. J Neuroimaging. 2016 Jul;26 (4) :403-5.|[3]Elsherbiny NM, et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93 (2-3) :78-88.